Izrael - angielski - Ministry of Health

pharmalogic ltd - irinotecan hydrochloride trihydrate 20 mg / 1 ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

Izrael - angielski - Ministry of Health

pharmalogic ltd - risperidone 1 mg - film coated tablets - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidone is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

Izrael - angielski - Ministry of Health

pharmalogic ltd - risperidone 2 mg - film coated tablets - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidone is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

Izrael - angielski - Ministry of Health

pharmalogic ltd - risperidone 3 mg - film coated tablets - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidone is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

Izrael - angielski - Ministry of Health

pharmalogic ltd - risperidone 4 mg - film coated tablets - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. risperidone is indicated for the treatment of psychotic manifestations of dementia. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years. risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

Izrael - angielski - Ministry of Health

pharmalogic ltd - gentamicin as sulfate - solution for injection - gentamicin as sulfate 80 mg / 2 ml - gentamicin - gentamicin is indicated in bacteremia, urinary tract infections, endocarditis, chest infections and other serious systemic infections due to confirmed or expected bacteria that are susceptible to gentamicin, in adults and children, including neonates.

Izrael - angielski - Ministry of Health

pharmalogic ltd - fulvestrant - solution for injection - fulvestrant 50 mg / 1 ml - fulvestrant - fulvestrant ever pharma 250 mg is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy,or* disease progression on endocrine therapy.combination therapy with palbociclib: fulvestrant ever pharma 250 mg is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)- negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.

Izrael - angielski - Ministry of Health

pharmalogic ltd - pemetrexed as disodium - concentrate for solution for infusion - pemetrexed as disodium 25 mg / 1 ml - pemetrexed - pemetrexed ever pharma 25 mg/ml in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed ever pharma 25 mg/ml in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed ever pharma 25 mg/ml is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed ever pharma 25 mg/ml is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Izrael - angielski - Ministry of Health

pharmalogic ltd - cabazitaxel - concentrate for solution for infusion - cabazitaxel 10 mg / 1 ml - cabazitaxel - cabazitaxel is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel- containing treatment regimen.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - proxymetacaine hydrochloride, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: glycerol; benzalkonium chloride; hydrochloric acid; purified water; sodium hydroxide - indications as at 13 jan 2005 : alcaine eye drops are indicated for procedures in which a rapid and short-acting topical ophthalmic anaesthetic is indicated such as in cataract surgery and suture removal from the cornea, and in tonometry, gonioscopy, removal of corneal foreign bodies, conjunctival scraping for diagnostic purposes, and other short corneal and conjunctival procedures.